HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.

Abstract
Von Hippel-Lindau (VHL) syndrome is an inherited cancer syndrome in which 8-17 % of germline mutation carriers develop pancreatic neuroendocrine tumors (PNETs). There is limited data on prognostic markers for PNETs other than Ki-67, which is included in the World Health Organization classification system. Recently, specific genes and pathways have been identified by whole exome sequencing which may be involved in the tumorigenesis of PNETs and may be markers of disease aggressiveness. The objective of this study was to identify molecular markers of aggressive disease in VHL-associated PNETs. The protein expression of eight genes (PTEN, CHGA, CHGB, ATRX, DAXX, CC-3, VEGF, and TP53) was analyzed in PNETs by immunohistochemistry and compared to clinical data, VHL genotype, functional imaging results, and pathologic findings. Subcellular distribution of phosphatase and tensin (PTEN), chromogranin A (CHGA), and alpha thalassemia/mental retardation syndrome X-linked (ATRX) were significantly different by WHO classifications (p ≤ 0.05). There was decreased PTEN nuclear to cytoplasmic ratio (p < 0.01) and decreased CHGA nuclear expression (p = 0.03) in malignant samples as compared to benign. Lower cytoplasmic chromogranin B (CHGB) expression (p = 0.03) was associated with malignant tumors and metastasis. Higher nuclear expression of PTEN was associated with VHL mutations in exon 3 (p = 0.04). Higher PTEN and CHGB expression was associated with higher FDG-PET avidity (p < 0.05). Cytoplasmic expression of CC-3 was associated with higher serum chromogranin A levels (ρ = 0.72, p = 0.02). Lastly, greater cytoplasmic expression of p53 was associated with metastasis. Our findings suggest that altered PTEN, ATRX, CHGA, and CHGB expression are associated with aggressive PNET phenotype in VHL and may serve as useful adjunct prognostic markers to Ki-67 in PNETs.
AuthorsAllison B Weisbrod, Lisa Zhang, Meenu Jain, Stephanie Barak, Martha M Quezado, Electron Kebebew
JournalHormones & cancer (Horm Cancer) Vol. 4 Issue 3 Pg. 165-75 (Jun 2013) ISSN: 1868-8500 [Electronic] United States
PMID23361940 (Publication Type: Journal Article, Research Support, N.I.H., Intramural)
Chemical References
  • CHGA protein, human
  • CHGB protein, human
  • Chromogranin A
  • Chromogranin B
  • Ki-67 Antigen
  • Nuclear Proteins
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • DNA Helicases
  • ATRX protein, human
  • X-linked Nuclear Protein
Topics
  • Adult
  • Aged
  • Chromogranin A (genetics)
  • Chromogranin B (genetics)
  • DNA Helicases (genetics)
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Ki-67 Antigen (genetics)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neuroendocrine Tumors (complications, genetics, pathology)
  • Nuclear Proteins (genetics)
  • PTEN Phosphohydrolase (genetics)
  • Pancreatic Neoplasms (complications, genetics, pathology)
  • Prognosis
  • Tumor Suppressor Protein p53 (genetics)
  • X-linked Nuclear Protein
  • von Hippel-Lindau Disease (complications, genetics, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: